BNTC director granted 28,517 options at $15.78; vest by 2026

Q: What did BNTC disclose in this Form 4?

A director was granted options to buy 28,517 shares at an exercise price of $15.78 on 11/05/2025.

Q: When do the BNTC director’s options vest?

They vest in full on the earlier of immediately prior to the 2026 annual meeting or November 5, 2026.

Q: What is the expiration date of the options reported by BNTC?

The options expire on 11/05/2035.

Q: How many derivative securities does the BNTC director hold after the grant?

The director beneficially owns 28,517 derivative securities directly after the reported transaction.

Q: Was any cash paid for the option grant?

The filing lists the price of the derivative security as $0, indicating a grant.

Benitec Biopharma (BNTC) reported an insider equity award.

Accepted by SEC EDGAR 11/07/2025 - 07:50 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Benitec Biopharma (BNTC) reported an insider equity award. A director received options to purchase 28,517 shares on 11/05/2025 at an exercise price of $15.78 per share. These options were granted for $0 and expire on 11/05/2035. The award will vest in full on the earlier of immediately prior to the company’s 2026 annual meeting of stockholders or November 5, 2026. Following the grant, the director holds 28,517 derivative securities directly.

Insider Trade Summary

Grant/Award: 28,517 shares

Grant/Award 1 txn

Insider Mates Sharon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	28,517	$0.00	$0.00

Holdings After Transaction: Options (right to buy) — 28,517 contracts (Direct)

Holdings Before and After: Options (right to buy), 0 to 28,517 contracts (Direct)

Footnotes (1)

F1. The Options will vest in full on the earlier of immediately prior to the Issuer's 2026 annual meeting of stockholders and November 5, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BNTC disclose in this Form 4?

A director was granted options to buy 28,517 shares at an exercise price of $15.78 on 11/05/2025.

When do the BNTC director’s options vest?

They vest in full on the earlier of immediately prior to the 2026 annual meeting or November 5, 2026.

What is the expiration date of the options reported by BNTC?

The options expire on 11/05/2035.

How many derivative securities does the BNTC director hold after the grant?

The director beneficially owns 28,517 derivative securities directly after the reported transaction.

Was any cash paid for the option grant?

The filing lists the price of the derivative security as $0, indicating a grant.

Is the reporting person a director or officer at BNTC?

The filing identifies the reporting person’s relationship as Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mates Sharon

(Last)

(First)

(Middle)

C/O BENITEC BIOPHARMA INC.

3940 TRUST WAY

(Street)

HAYWARD

94545

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options (right to buy)	$15.78	11/05/2025		A		28,517		⁽¹⁾	11/05/2035	Common Stock	28,517	$0	28,517	D

Explanation of Responses:

1. The Options will vest in full on the earlier of immediately prior to the Issuer's 2026 annual meeting of stockholders and November 5, 2026.

	/s/ Sharon Mates	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR